B3GNT9

Across TCGA pan-cancer cohorts, B3GNT9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated B3GNT9 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher B3GNT9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated B3GNT9 expression acts as an unfavorable survival marker.

SKCM, LIHC, and UCEC are the cancer types where B3GNT9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.044	0.738	<.001	18	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

B3GNT9–SKCM (DFS)

Open the SKCM breakdown →